CN103463624A - Bone joint composite nutrient supplement and preparation method thereof - Google Patents
Bone joint composite nutrient supplement and preparation method thereof Download PDFInfo
- Publication number
- CN103463624A CN103463624A CN2013104286681A CN201310428668A CN103463624A CN 103463624 A CN103463624 A CN 103463624A CN 2013104286681 A CN2013104286681 A CN 2013104286681A CN 201310428668 A CN201310428668 A CN 201310428668A CN 103463624 A CN103463624 A CN 103463624A
- Authority
- CN
- China
- Prior art keywords
- osteoarthrosis
- extract
- olibanum
- composite nourishing
- nourishing energizing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002131 composite material Substances 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 210000000988 bone and bone Anatomy 0.000 title abstract description 8
- 235000015872 dietary supplement Nutrition 0.000 title abstract description 7
- 239000000284 extract Substances 0.000 claims abstract description 46
- 239000000203 mixture Substances 0.000 claims abstract description 37
- 241000717739 Boswellia sacra Species 0.000 claims abstract description 36
- 239000004863 Frankincense Substances 0.000 claims abstract description 36
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims abstract description 33
- 102000008186 Collagen Human genes 0.000 claims abstract description 23
- 108010035532 Collagen Proteins 0.000 claims abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 23
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 20
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 20
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 19
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 19
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 19
- 238000000746 purification Methods 0.000 claims abstract description 8
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 39
- 239000003795 chemical substances by application Substances 0.000 claims description 27
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 26
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 20
- 229960002442 glucosamine Drugs 0.000 claims description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 7
- 238000000643 oven drying Methods 0.000 claims description 7
- 239000012467 final product Substances 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 3
- 230000003412 degenerative effect Effects 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 238000010992 reflux Methods 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 14
- 208000024891 symptom Diseases 0.000 abstract description 8
- 206010003246 arthritis Diseases 0.000 abstract description 5
- 229920001436 collagen Polymers 0.000 abstract description 5
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 abstract description 4
- 229960001911 glucosamine hydrochloride Drugs 0.000 abstract description 4
- 238000001035 drying Methods 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 238000000605 extraction Methods 0.000 abstract description 2
- 229940016409 methylsulfonylmethane Drugs 0.000 abstract 3
- 229920002567 Chondroitin Polymers 0.000 abstract 2
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 abstract 2
- 235000003717 Boswellia sacra Nutrition 0.000 abstract 1
- 235000012035 Boswellia serrata Nutrition 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 24
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 20
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 20
- 238000011282 treatment Methods 0.000 description 13
- 208000002193 Pain Diseases 0.000 description 12
- 235000019359 magnesium stearate Nutrition 0.000 description 12
- 230000036407 pain Effects 0.000 description 12
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 10
- 229930003268 Vitamin C Natural products 0.000 description 10
- 239000001506 calcium phosphate Substances 0.000 description 10
- 229910000389 calcium phosphate Inorganic materials 0.000 description 10
- 235000011010 calcium phosphates Nutrition 0.000 description 10
- 239000004203 carnauba wax Substances 0.000 description 10
- 238000004040 coloring Methods 0.000 description 10
- 229940099596 manganese sulfate Drugs 0.000 description 10
- 239000011702 manganese sulphate Substances 0.000 description 10
- 235000007079 manganese sulphate Nutrition 0.000 description 10
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 10
- 229920000609 methyl cellulose Polymers 0.000 description 10
- 239000001923 methylcellulose Substances 0.000 description 10
- 235000010981 methylcellulose Nutrition 0.000 description 10
- 239000008108 microcrystalline cellulose Substances 0.000 description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 description 10
- 239000000377 silicon dioxide Substances 0.000 description 10
- 239000004408 titanium dioxide Substances 0.000 description 10
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 10
- 239000011718 vitamin C Substances 0.000 description 10
- 235000019154 vitamin C Nutrition 0.000 description 10
- 229910021538 borax Inorganic materials 0.000 description 9
- 235000010339 sodium tetraborate Nutrition 0.000 description 9
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 9
- 208000012659 Joint disease Diseases 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 239000003623 enhancer Substances 0.000 description 8
- 235000016709 nutrition Nutrition 0.000 description 8
- 230000035764 nutrition Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 235000012239 silicon dioxide Nutrition 0.000 description 7
- 210000001188 articular cartilage Anatomy 0.000 description 6
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000000845 cartilage Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000008822 Ankylosis Diseases 0.000 description 3
- 206010023198 Joint ankylosis Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 206010005963 Bone formation increased Diseases 0.000 description 1
- -1 Dichlorodiphenyl Acetate Chemical compound 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000036319 cervical spondylosis Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 208000005801 spondylosis Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a bone joint composite nutrient supplement and a preparation method thereof. The bone joint composite nutrient supplement comprises the following components in parts by weight: 350-600 parts of glucosamine hydrochloride, 350-450 parts of chondroitin/MSM (methyl sulfonyl methane) mixture and 16-60 parts of traditional Chinese medicine extract, wherein the chondroitin/MSM mixture comprises chondroitin sulfate, dimethyl sulfone, collagen, frankincense and hyaluronic acid according to weight part of 2:3:1:1:3, the extraction process of the traditional Chinese medicine extract comprises the steps of smashing clean traditional Chinese medicinal materials, heating and back flowing for 2-3 hours by a low solubility ethyl alcohol solution, extracting for 3 times, combining the extracting solutions, after purification, concentrating, and drying at low temperature. The bone joint composite nutrient supplement not only can improve various arthritis and symptoms caused by arthritis, but also can improve various symptoms caused by osteoporosis.
Description
Technical field
the invention belongs to nutriment health preparation technical field, more specifically say a kind of osteoarthrosis composite nourishing energizing agent and preparation method thereof.
Background technology
osteoarthritis very common joint disease in the diseases of middle-and old-aged person, it can cause arthralgia and ankylosis, can cause to middle-older patient, cause certain handicapped.The traditional treatment joint disease, comprise common gonarthritis, cervical spondylosis, prolapse of lumbar intervertebral disc, hyperosteogeny (bony spur), scapulohumeral periarthritis etc., mainly contains the methods such as naturopathy, operative treatment, Drug therapy.These methods can only the respite symptom, can not reach the purpose of basic treatment.The life-time service drug side effect is large simultaneously, and untoward reaction is serious, and especially hormone medicine, can bring out the more serious diseases such as hypertension, diabetes, glaucoma, and can draw backlash after drug withdrawal, causes symptom further to increase the weight of.For a long time, due to the understanding lacked the pathogenic basic reason of joint disease, the treatment of joint disease is always for symptom treatments such as pain, swelling, be in the refractory condition originally of taking stopgap measures, in the time for the treatment of, disease continues development, finally cause joint deformity, tetanic, function completely loses, and is paralyzed in bed, and can't take care of oneself.Scientific research proves, and osteoarthritis (also claiming osteoarthritis) is a kind of known joint degenerative disease, and its basic reason is destruction and the forfeiture of articular cartilage, and in brief, arthritis-disease is in joint, and root is at cartilage.Therefore, the correct effective method for the treatment of joint disease is to repair damaged articular cartilage, supplements glucosamine, bone collagen (II collagen type) and chondroitin sulfate etc. simultaneously, and antiinflammatory, analgesia, reparation chondrocyte, settle at one go.At present, in worldwide, glucosamine, bone collagen, chondroitin sulfate be as the supplementary targetedly of articular cartilage, by medical circle be known as can the thorough improvement joint disease the specificity preparation.Glucosamine, bone collagen, chondroitin sulfate are all the natural components be present in articular cartilage, research worker is thought, they can be by promoting that Human Osteoarthritis forms new articular cartilage, slow down the forfeiture of articular cartilage, can also the alleviating pain symptom, keep the motility of joint motions.
Summary of the invention
it not only can be used as the health food of prevention osteoarticular injury, the poor disease of human synovial fluid and exhaustion and the anti-ageing diet nutritional supplement of waiting for a long time osteoarthrosis nutrition enhancer of the present invention, and, through further clinical practice exploitation, can be made into the specific medicament for the treatment of osteoarthritis.
the invention discloses a kind of osteoarthrosis composite nourishing energizing agent for this reason, it is characterized in that it is comprised of glucosamine hydrochoride, chrondroitin/MSM mixture, Chinese medicine extract, wherein glucosamine hydrochoride: chrondroitin/MSM mixture: the ratio of weight and number of Chinese medicine extract is 350-600 part: 350-450 part: 16-60 part; It take described chrondroitin/MSM mixture ratio of weight and number by chondroitin sulfate, dimethyl sulfone, collagen protein, Olibanum, hyaluronic acid and forms as 2:3:1:1:3; Described Chinese medicine extract refers to Olibanum extract or/and Herba Epimedii.
chinese medicine extract of the present invention refers to: clean Olibanum or Herba Epimedii pulverized, with ethanol (35%-60%) vlil 2-3 hour, extracted three times, and merge extractive liquid,, after carrying out purification process, concentrated, oven drying at low temperature gets final product.
osteoarthrosis composite nourishing energizing agent of the present invention, wherein the molecular weight of collagen protein is 1000 dalton.Hyaluronic acid refers to molecular weight from 5,000 to 2,000 ten thousand Dao Er, preferably clear matter acid 5000 molecular weight Dao Er.
osteoarthrosis composite nourishing energizing agent of the present invention refers to oral formulations.Preferred tablet or capsule.
its each component content of the preferred oral formulations tablet of the present invention:
glucosamine hydrochoride: 350mg---600mg chrondroitin mixture: 350mg--450mg
chinese medicine extract: 16mg---60mg calcium phosphate: 0.1mg-8mg
sodium borate 7mg-20mg vitamin C 13mg-26mg
manganese sulfate 1---4mg methylcellulose 1-4mg
burnt sugar coloring 1-4mg microcrystalline Cellulose 2-6mg
silica 1--3mg titanium dioxide 1-5mg
magnesium stearate 1--4mg palm wax 0.3---2mg;
it take described chrondroitin/MSM mixture ratio of weight and number by chondroitin sulfate, dimethyl sulfone, collagen protein, Olibanum, hyaluronic acid and forms as 2:3:1:1:3; Described Chinese medicine extract refers to Olibanum extract or/and Herba Epimedii.
the tablet each component content be more preferably:
glucosamine hydrochoride 500mg/ sheet chrondroitin/MSM design of mixture 396mg/ sheet
chinese medicine extract: 33.3mg calcium phosphate: 4mg
sodium borate: 13.3mg vitamin C: 60mg
manganese sulfate: 2mg methylcellulose: 3mg
burnt sugar coloring: 2mg microcrystalline Cellulose: 3mg
silicon dioxide: 3mg titanium dioxide: 4mg
magnesium stearate: 3mg palm wax: 0.8mg;
it take described chrondroitin/MSM mixture ratio of weight and number by chondroitin sulfate, dimethyl sulfone, collagen protein, Olibanum, hyaluronic acid and forms as 2:3:11:3; Described Chinese medicine extract refers to Olibanum extract or/and Herba Epimedii.Leaching process: clean Olibanum or Herba Epimedii are pulverized, with ethanol (35%-60%) vlil 2-3 hour, extracted three times, merge extractive liquid,, after carrying out purification process, concentrated, oven drying at low temperature, standby.
chondroitin sulfate is the acidic mucopolysaccharide obtained from the extraction of the cartilages such as mammal trachea.It has the clarification lipid, improves the body function of detoxification, the effects such as diuresis and analgesia (having commercially available).
in every 3 of osteoarthrosis nutrition enhancer of the present invention, add: glucosamine hydrochoride 1500mg, chrondroitin/MSM design of mixture 1250mg, Olibanum extract 100mg.
through pharmacological evaluation, confirm: Herba Epimedii has the effect while of androgen sample, and Herba Epimedii can also suppress vasomotor center, and the expansion peripheral vessels, make the blood pressure drops Herba Epimedii be mainly used in clinically treating joint disease.Add Herba Epimedii extract and can improve old people's hormonal readiness, blood vessel dilating, promote the repair of cartilage growth.
through pharmacological evaluation, confirm: Olibanum extract can antiphlogistic antibacterial, contributes to alleviate arthralgia, improve aspect knee comfortableness and activeness effective.
osteoarthrosis composite nourishing energizing agent of the present invention, wherein the molecular weight of collagen protein is 1000 dalton.Hyaluronic acid refers to molecular weight from 5,000 to 2,000 ten thousand Dao Er, and preferably clear matter acid molecule amount is 5000 Dao Er.Described osteoarthrosis nutrition enhancer refers to oral formulations, for example tablet or capsule.
oral formulations of the present invention refers to its each component content of tablet:
glucosamine hydrochoride: 350mg--600mg ossein mixture: 350mg--450mg
olibanum extract or Herba Epimedii extract: 16mg-60mg calcium phosphate: 0.1mg--8mg
sodium borate 7mg-20mg vitamin C 13mg--26mg
manganese sulfate 1--4mg methylcellulose 1-4mg
burnt sugar coloring 1-4mg microcrystalline Cellulose 2-6mg
silica 1--3mg titanium dioxide 1-5mg
magnesium stearate 1--4mg palm wax 0.3---2mg;
tablet test report:
| Sequence number | Detection material | Requirement | Actual measurement |
| 1 | Glucosamine hydrochoride | 350mg-600mg | 510mg |
| 2 | Chrondroitin/MSM design of mixture (chondroitin sulfate, dimethyl sulfone (MSM), collagen protein, Olibanum, hyaluronic acid), | 350mg-450mg | 398mg |
| 3 | Olibanum extract | 16mg---60mg | 35.3mg |
| 4 | Calcium phosphate | 0.1mg—8mg | 4 |
| 5 | Sodium borate | 7mg—20mg | 17.3mg |
| 6 | Vitamin C | 13mg----26mg | 68mg |
| 7 | Manganese sulfate | 1 mg ----4mg | 2mg |
| 8 | Methylcellulose | 1 mg—4mg | 3mg |
| 9 | Burnt sugar coloring | 1 mg--—4mg | 2mg |
| 10 | Microcrystalline Cellulose | 2 mg ---6mg | 3mg |
| 11 | Silicon dioxide | 1 mg ---3mg | 3mg |
| 12 | Titanium dioxide | 1 mg—5mg | 4mg |
| 13 | Magnesium stearate | 1 mg ---4mg | 3mg |
| 14 | Palm wax | 0.3 mg ---2mg | 0.8mg |
another typical formula of the present invention is as follows:
composition: glucosamine hydrochoride chrondroitin/design of mixture (chondroitin sulfate, collagen protein, Olibanum, hyaluronic acid), Herba Epimedii extract, Olibanum extract, vitamin C, manganese sulfate, methylcellulose, burnt sugar coloring, microcrystalline Cellulose, silicon dioxide, titanium dioxide, magnesium stearate, palm wax calcium phosphate;
each component content:
glucosamine hydrochoride: 350mg-600mg/ sheet chrondroitin mixture: 350mg-450mg/ sheet
herba Epimedii extract: 0.3--0.85mg/ sheet Olibanum extract: 16mg-60mg/ sheet
sodium borate 7mg--20mg/ sheet vitamin C 13mg--26mg/ sheet
manganese sulfate: 1 mg-4mg/ sheet methylcellulose 1mg-4mg/ sheet
burnt sugar coloring 1mg-4mg/ sheet microcrystalline Cellulose 2 mg-6mg/ sheets
silica 1 mg-3mg/ sheet titanium dioxide 1mg-5mg/ sheet
magnesium stearate 1 mg-4mg/ sheet palm wax 0.3mg-2mg/ sheet
calcium phosphate: 0.1mg--8mg/ sheet;
it take ratio of weight and number as chondroitin sulfate by chondroitin sulfate, dimethyl sulfone, collagen protein, Olibanum, hyaluronic acid described chrondroitin/MSM mixture: dimethyl sulfone: collagen protein: Olibanum: hyaluronic acid 2:3:1:1:3 forms survey report:
| Sequence number | Detection material | Requirement | Actual measurement |
| 1 | Glucosamine hydrochoride | 350mg---600mg | 510mg |
| 2 | Chrondroitin/MSM design of mixture (be take ratio of weight and number as chondroitin sulfate: dimethyl sulfone: collagen protein: Olibanum: hyaluronic acid 2:3:1:1:3) | 350mg----450mg | 398mg |
| 3 | Herba Epimedii extract | 0.3 mg ---0.85mg | 70mg |
| 4 | Olibanum extract | 16mg---60mg | 35.3mg |
| 5 | Sodium borate | 7mg—20mg | 17.3mg |
| 6 | Vitamin C | 13mg----26mg | 68mg |
| 8 | Manganese sulfate | 1 mg ----4mg | 2mg |
| 9 | Methylcellulose | 1 mg—4mg | 3mg |
| 10 | Burnt sugar coloring | 1 mg--—4mg | 2mg |
| 11 | Microcrystalline Cellulose | 2 mg ---6mg | 3mg |
| 12 | Silicon dioxide | 1 mg ---3mg | 3mg |
| 13 | Titanium dioxide | 1 mg—5mg | 4mg |
| 14 | Magnesium stearate | 1 mg ---4mg | 3mg |
| 15 | Palm wax | 0.3 mg ---2mg | 0.8mg |
| 16 | Calcium phosphate | 0.1mg—8mg | 4 |
the preparation method of osteoarthrosis composite nourishing energizing agent of the present invention, adopt conventional method for preparing tablet thereof, for example can say various raw material mix homogeneously, add appropriate 10% hydroxypropyl methylcellulose solution to granulate, drying, then add carboxymethyl starch sodium etc., magnesium stearate, mix, tabletting.
the present invention further discloses the application of osteoarthrosis composite nourishing energizing agent in improving Senile degenerative osteopathia medicine, particularly improve the application in medicine for treating osteoporosis.
below provide the pharmacological experimental data that the present invention improves the osteoarthrosis composite nourishing energizing agent, and concrete pharmacodynamics and toxicity test result be summarized as follows:
one, pharmacodynamics test:
1, osteoarthrosis composite nourishing energizing agent on Carrageenan of the present invention causes the swollen inhibitory action (arthritis test) of rat foot:
osteoarthrosis composite nourishing energizing agent on Carrageenan of the present invention cause rat foot swollen inhibitory action arranged, result of the test shows, the osteoarthrosis composite nourishing energizing agent is 25,50 and during 100mg/kg in dosage, respectively at after administration 0.5,1,2,3 and 4 hour, the rat foot being swollen to rise all has obvious inhibitory action (P<0.01), and positive control drug glucosamine hydrochloride (50mg/kg) has identical inhibitory action (P<0.01).
, osteoarthrosis composite nourishing energizing agent of the present invention is to the analgesic activity (acetic acid twisting test) of mice:
result of the test shows, the oral osteoarthrosis composite nourishing energizing agent of the present invention of mice, at dosage, be 25,50 and during 100mg/kg, the mice pain that Dichlorodiphenyl Acetate causes all has inhibitory action in various degree, compare (P<0.05,0.05 and 0.01) with model group, with contrasting, medicine glucosamine hydrochloride (50mg/kg) effect is suitable.
, osteoarthrosis nutrition enhancer of the present invention is to the refrigeration function (endotoxin pyrogenic) of rabbit:
result of the test shows, the rabbit gavage gives osteoarthrosis nutrition enhancer 50 of the present invention and 100mg/kg, all can suppress rabbit and raise (P<0.05), and inhibitory action continues 1～2 hour, and with contrast, medicine glucosamine hydrochloride (50mg/kg) effect is suitable.
mice with Cmax, oral administration gavage osteoarthrosis composite nourishing energizing agent of the present invention 2g/kg of maximum administration volume after, the mental status is good, autonomic activities is normal, breathe, heart rate is normal, Continuous Observation one week, body weight gain is normal, have no any toxic reaction, without the phenomena of mortality.Therefore, the median lethal dose(LD 50) LD of bone osteoarthrosis composite nourishing energizing agent gastric infusion of the present invention
50
2g/kg.
the clinical trial situation that osteoarthrosis composite nourishing energizing agent prepared by the present invention carries out is as follows:
the index of osteopathia rehabilitation:
1. alleviating pain; 2. anti-inflammation detumescence; 3. keep muscular strength, function of joint; 4. prevention/correct deformity;
5. improve the ADL ability; 6. Saving cortilage, maintain or increase range of motion; 7. no longer recurrence after rehabilitation.
observation item:
1, clinical observation: leading indicator is the parameters for observation on effect total points, and this total points is according to playing the cumulative gained of ankylosis scoring in articular pain, level walking pain, rest pain, morning.Wherein level walking bitterly mark and rest pain scoring according to the VAS pain scores, and play the ankylosis scoring in articular pain and morning according to the scoring of testing program standards of grading (light according to the order of severity, in, heavily be respectively 0,1,2 minutes)
2, lab index: after reaching treatment before treatment, 4,8,12wk does respectively blood, urine, just conventional, electrocardiogram, liver, renal function, blood glucose inspection.
method: 192 routine morning, middle knee osteoarthritis patient are divided into 3 groups at random:
experimental group 64 examples, take 2 courses for the treatment of of osteoarthrosis nutrition enhancer, every day consumption 3.3 grams;
matched group 64 examples give the oral hydrochloride glucosamine 2 courses for the treatment of, every day consumption 3.3 grams;
blank group 64 examples, only used placebo.
result of the test is as following table:
the therapeutic evaluation of table 1 treatment situation improvement rate relatively
discuss:
d-glucosamine is one of main constituent of picked-up formation cartilage proteoglycan, can relax the pain because of arthronosos deformans, and prevents continuing of deterioration.Chondroitin sulfate have the smooth effect in joint that keeps, and participates in manufacturing skeleton.Dimethyl sulfone can be safeguarded the balance of human-body biological element sulphur, by blood circulation and channel invigorating, promotes the conveying of nutrient substance and functional component, the action and efficacy of strengthening D-glucosamine chrondroitin.Collagen protein is the skeleton in skeleton, promotes the basic of osteanagenesis.The dietary supplement that contains single D-glucosamine composition can only relax the osteopathia symptom, can not farthest cure osteopathia, only has by the interaction between them, and the success rate of curing osteopathia just can farthest be improved.Above-mentioned experiment shows:
(1) the taking dose matched group is compared with experimental group, takes the same dosage of D-glucosamine and nutrition enhancer.
(2) the therapeutic effect matched group is compared with experimental group, and general effect is better than the matched group of single use D-glucosamine.。
(3) classical symptom improves main manifestations for greatly shortening time and the pain degree of deadlock in morning, the mobility in increase joint.
conclusion:
the blocking-up inflammation develops, repairs impaired synovial membrane and cartilage, is the important step of curing joint disease.Result shows: the osteoarthrosis nutrition enhancer of taking synthetic prescription will obviously be better than taking merely the dietary supplement of D-glucosamine composition to the therapeutic effect of osteopathia.
embodiment
below in conjunction with embodiment, the present invention is described, the scheme of embodiment described here, do not limit the present invention, one of skill in the art can make improvements and change according to spirit of the present invention, described these improvement and variation all should be considered as within the scope of the invention, and scope of the present invention and essence are limited by claim.Active component Herba Epimedii extract used, Olibanum extract have commercially available, also can be by the method preparation of embodiment.
glucosamine hydrochoride is bought in ZHEJIANG AOXING BIOTECHNOLOGY CO., LTD.
chondroitin sulfate is bought in the precious bio tech ltd of Shandong benefit.
dimethyl sulfone is bought in Wuhan Yi Huacheng Chemical Industry Science Co., Ltd.
collagen protein is bought in holy day science and technology of Tianjin gold limitedcompany
.
hyaluronic acid is bought in Hubei Yuancheng Pharmaceutical Co., Ltd..
embodiment 1
glucosamine hydrochoride 500mg/ sheet
chrondroitin/MSM design of mixture (be take ratio of weight and number as chondroitin sulfate: dimethyl sulfone: collagen protein: Olibanum: hyaluronic acid 2:3:1:1:3) 396mg/ sheet
olibanum extract: 33.3mg calcium phosphate: 4mg sodium borate: 13.3mg
vitamin C: 60mg manganese sulfate: 2mg methylcellulose: 3mg
burnt sugar coloring: 2mg microcrystalline Cellulose: 3mg silicon dioxide: 3mg
titanium dioxide: 4mg magnesium stearate: 3mg palm wax: 0.8mg.
olibanum extract: refer to clean Olibanum, with hanging down solubility 60% ethanol (w/w) vlil 2 hours, extract three times, merge extractive liquid,, after carrying out purification process, concentrated, oven drying at low temperature gets final product.
embodiment 2
glucosamine hydrochoride 500mg/ sheet chrondroitin/MSM design of mixture 396mg/ sheet
herba Epimedii extract: 33.3mg calcium phosphate: 4mg sodium borate: 13.3mg
vitamin C: 60mg manganese sulfate: 2mg methylcellulose: 3mg
burnt sugar coloring: 2mg microcrystalline Cellulose: 3mg silicon dioxide: 3mg
titanium dioxide: 4mg magnesium stearate: 3mg palm wax: 0.8mg;
it is by take ratio of weight and number as chondroitin sulfate for described chrondroitin/MSM mixture: dimethyl sulfone: collagen protein: Olibanum: hyaluronic acid 2:3:1:1:3.
herba Epimedii extract: refer to clean Olibanum, with hanging down solubility 40% ethanol (w/w) vlil 3 hours, extract three times, merge extractive liquid,, after carrying out purification process, concentrated, oven drying at low temperature gets final product.
embodiment 3
glucosamine hydrochoride 500mg/ sheet
chrondroitin/MSM design of mixture 396mg/ sheet
herba Epimedii extract: 60.5mg Olibanum extract: 33.3mg sodium borate: 13.3mg
vitamin C: 60mg manganese sulfate: 2mg methylcellulose: 3mg
burnt sugar coloring: 2mg microcrystalline Cellulose: 3mg silicon dioxide: 3mg
titanium dioxide: 4mg magnesium stearate: 3mg palm wax: 0.8mg
calcium phosphate: 4mg.
it is by take ratio of weight and number as chondroitin sulfate for described chrondroitin/MSM mixture: dimethyl sulfone: collagen protein: Olibanum: hyaluronic acid 2:3:1:1:3.
herba Epimedii extract: refer to clean Herba Epimedii, with hanging down solubility ethanol (35%) vlil 3 hours, extract three times, merge extractive liquid,, after carrying out purification process, concentrated, oven drying at low temperature gets final product.
olibanum extract: refer to clean Olibanum, with hanging down solubility ethanol (35%) vlil 2 hours, extract three times, merge extractive liquid,, after carrying out purification process, concentrated, oven drying at low temperature gets final product.
embodiment 4
the preparation of embodiment 1-3 tablet:
By the above-mentioned raw materials mix homogeneously, add appropriate 10% hydroxypropyl methylcellulose solution to granulate, drying, then add carboxymethyl starch sodium, magnesium stearate, mix, tabletting.
Claims (9)
1. an osteoarthrosis composite nourishing energizing agent, it is characterized in that it is comprised of glucosamine hydrochoride, chrondroitin/MSM mixture, Chinese medicine extract, wherein glucosamine hydrochoride: chrondroitin/MSM mixture: the ratio of weight and number of Chinese medicine extract is 350-600 part: 350-450 part: 16-60 part; It take ratio of weight and number as chondroitin sulfate by chondroitin sulfate, dimethyl sulfone, collagen protein, Olibanum, hyaluronic acid described chrondroitin/MSM mixture: dimethyl sulfone: collagen protein: Olibanum: hyaluronic acid 2:3:1:1:3 forms; Described Chinese medicine extract refers to Olibanum extract or/and Herba Epimedii extract.
2. osteoarthrosis composite nourishing energizing agent claimed in claim 1, Chinese medicine extract wherein refers to pulverizes clean Olibanum or Herba Epimedii, with 35%-60% alcoholic solution reflux 2-3 hour, extract three times, merge extractive liquid,, after carrying out purification process, concentrated, oven drying at low temperature gets final product.
3. osteoarthrosis composite nourishing energizing agent claimed in claim 1, wherein the molecular weight of collagen protein is 1000 dalton.
4. osteoarthrosis composite nourishing energizing agent claimed in claim 1, hyaluronic acid wherein refers to molecular weight from 5,000 to 2,000 ten thousand Dao Er.
5. osteoarthrosis composite nourishing energizing agent claimed in claim 4, it is 5000 Dao Er that hyaluronic acid wherein refers to molecular weight.
6. osteoarthrosis composite nourishing energizing agent claimed in claim 1, hardening agent wherein refers to oral formulations.
7. osteoarthrosis composite nourishing energizing agent claimed in claim 6, oral formulations wherein refers to tablet or capsule.
8. the described osteoarthrosis composite nourishing energizing agent of claim 1 improves the application in Senile degenerative osteopathia medicine in preparation.
9. the described osteoarthrosis composite nourishing energizing agent of claim 1 improves the application in medicine for treating osteoporosis in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013104286681A CN103463624A (en) | 2013-09-22 | 2013-09-22 | Bone joint composite nutrient supplement and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013104286681A CN103463624A (en) | 2013-09-22 | 2013-09-22 | Bone joint composite nutrient supplement and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103463624A true CN103463624A (en) | 2013-12-25 |
Family
ID=49788813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013104286681A Pending CN103463624A (en) | 2013-09-22 | 2013-09-22 | Bone joint composite nutrient supplement and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103463624A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105770864A (en) * | 2016-04-08 | 2016-07-20 | 杭州合研科技有限公司 | Composition with function of relieving joint inflammation pain |
| CN106072651A (en) * | 2016-07-19 | 2016-11-09 | 山东明仁福瑞达制药股份有限公司 | A kind of have compositions increasing bone density, anti-inflammatory and analgesic effect and preparation method thereof |
| CN110946874A (en) * | 2019-12-27 | 2020-04-03 | 华熙生物科技股份有限公司 | Hyaluronic acid composition for relieving osteoarthritis |
| CN111280447A (en) * | 2018-12-07 | 2020-06-16 | 解冰 | Composite nanometer preparation for treating and recovering bone joint function and preparation method thereof |
| CN112826925A (en) * | 2021-04-12 | 2021-05-25 | 仕医堂(吉林)生物药业有限公司 | Traditional Chinese medicine liquid for treating osteoarticular diseases and preparation method thereof |
| CN113662739A (en) * | 2021-08-20 | 2021-11-19 | 刘浩泉 | Ice compress and manufacturing method thereof |
| CN116726141A (en) * | 2023-08-09 | 2023-09-12 | 华润圣海健康科技有限公司 | Composition for preventing and relieving osteoarthropathy and application thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1364464A (en) * | 2002-01-29 | 2002-08-21 | 郑刚 | Aminoglucose hydrochloride medicinal composition |
| CN1771046A (en) * | 2003-04-11 | 2006-05-10 | 协和发酵工业株式会社 | Preventive or therapeutic agent for arthritis |
| US20080138417A1 (en) * | 2006-11-22 | 2008-06-12 | Charles Grigsby | Topical Composition And Method Of Forming |
| WO2009153200A1 (en) * | 2008-06-18 | 2009-12-23 | Gertrud Langhoff | Preparation containing glucosamine and/or chondroitin for prophylaxis and treatment of arthrosis and for supporting the immune system |
| CN101961110A (en) * | 2010-10-14 | 2011-02-02 | 马宏达 | Preparation method of functional food for nourishing cartilage and resisting joint inflammation |
| CN103039997A (en) * | 2013-01-11 | 2013-04-17 | 湖南映荷生物科技有限公司 | Health-care food composition for increasing bone mineral density and preparation method |
-
2013
- 2013-09-22 CN CN2013104286681A patent/CN103463624A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1364464A (en) * | 2002-01-29 | 2002-08-21 | 郑刚 | Aminoglucose hydrochloride medicinal composition |
| CN1771046A (en) * | 2003-04-11 | 2006-05-10 | 协和发酵工业株式会社 | Preventive or therapeutic agent for arthritis |
| US20080138417A1 (en) * | 2006-11-22 | 2008-06-12 | Charles Grigsby | Topical Composition And Method Of Forming |
| WO2009153200A1 (en) * | 2008-06-18 | 2009-12-23 | Gertrud Langhoff | Preparation containing glucosamine and/or chondroitin for prophylaxis and treatment of arthrosis and for supporting the immune system |
| CN101961110A (en) * | 2010-10-14 | 2011-02-02 | 马宏达 | Preparation method of functional food for nourishing cartilage and resisting joint inflammation |
| CN103039997A (en) * | 2013-01-11 | 2013-04-17 | 湖南映荷生物科技有限公司 | Health-care food composition for increasing bone mineral density and preparation method |
Non-Patent Citations (2)
| Title |
|---|
| J. E. DECHANT 等: ""Effects of glucosamine hydrochloride and chondroitin sulphate, alone and in combination, on normal and interleukin-1 conditioned equine articular cartilage explant metabolism"", 《EQUINE VETERINARY JOURNAL》, vol. 37, no. 3, 31 May 2005 (2005-05-31), pages 227 - 231 * |
| 无: ""自然之宝葡萄糖胺软骨素MSM复合营养片"", 《百度百科》, 16 January 2012 (2012-01-16) * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105770864A (en) * | 2016-04-08 | 2016-07-20 | 杭州合研科技有限公司 | Composition with function of relieving joint inflammation pain |
| CN106072651A (en) * | 2016-07-19 | 2016-11-09 | 山东明仁福瑞达制药股份有限公司 | A kind of have compositions increasing bone density, anti-inflammatory and analgesic effect and preparation method thereof |
| CN106072651B (en) * | 2016-07-19 | 2019-08-23 | 山东明仁福瑞达制药股份有限公司 | It is a kind of with increasing bone density, composition of anti-inflammatory and analgesic effect and preparation method thereof |
| CN111280447A (en) * | 2018-12-07 | 2020-06-16 | 解冰 | Composite nanometer preparation for treating and recovering bone joint function and preparation method thereof |
| CN110946874A (en) * | 2019-12-27 | 2020-04-03 | 华熙生物科技股份有限公司 | Hyaluronic acid composition for relieving osteoarthritis |
| CN112826925A (en) * | 2021-04-12 | 2021-05-25 | 仕医堂(吉林)生物药业有限公司 | Traditional Chinese medicine liquid for treating osteoarticular diseases and preparation method thereof |
| CN112826925B (en) * | 2021-04-12 | 2022-09-06 | 仕医堂(吉林)生物药业有限公司 | Traditional Chinese medicine liquid for treating osteoarticular diseases and preparation method thereof |
| CN113662739A (en) * | 2021-08-20 | 2021-11-19 | 刘浩泉 | Ice compress and manufacturing method thereof |
| CN116726141A (en) * | 2023-08-09 | 2023-09-12 | 华润圣海健康科技有限公司 | Composition for preventing and relieving osteoarthropathy and application thereof |
| CN116726141B (en) * | 2023-08-09 | 2023-11-03 | 华润圣海健康科技有限公司 | Composition for preventing and relieving osteoarthropathy and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103463624A (en) | Bone joint composite nutrient supplement and preparation method thereof | |
| CN101342290B (en) | Tong bi liquid and preparation method thereof | |
| WO2021062888A1 (en) | Complex composition with function of promoting bone and joint health and application thereof | |
| CN102793870B (en) | Chinese herbal medicine for treating renal calculi | |
| CN101933963A (en) | A nasal in situ gel for treating headaches | |
| CN101480412A (en) | Honeybee four-treasure for treating prostatosis | |
| CN105056063B (en) | A kind of traditional Chinese medicine composition | |
| CN104288303A (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases | |
| CN100525792C (en) | Chinese medicine composition for treating angiitis and phlebitis | |
| CN103156865A (en) | Application of L-arabinose in preparing medicines or health-care products | |
| CN102188643B (en) | Medicament for treating damp-heat blockage syndrome and its preparation method | |
| Thakral et al. | Role of glucosamine in osteoarthritis | |
| CN101249236B (en) | Chinese and western medicine combined preparations for curing epileptic | |
| CN100522158C (en) | Application of Gulunbin, iso-gulunbin and fibleucin for preparing medicine for treating arthritis | |
| CN105267949A (en) | Medicine prescription for degenerative arthritis and osteoporosis and tablet preparation method thereof | |
| WO2016066068A1 (en) | Use of metallothionein composite formulation as medication for treating cerebral stroke sequelae by acupoint entry | |
| CN103142928A (en) | Iliacus muscle oral liquid and preparation method thereof | |
| CN103933476B (en) | It is a kind of to treat pharmaceutical composition of intercostal neuralgia and its production and use | |
| CN102058764B (en) | Medicinal composition for treating acquired immune deficiency syndrome (AIDS) and application thereof | |
| CN103157072B (en) | Chinese medicinal composition for treating cervical spondylosis | |
| CN104225014B (en) | A kind of Tibetan medicine for the treatment of diabetes | |
| CN105194545B (en) | A kind of Chinese medicine composition for treating asthma | |
| CN1233394C (en) | Reumatic arthritis treating medicine | |
| CN112535706A (en) | Medicine and food dual-purpose powder for repairing joints and preparation method and application thereof | |
| CN104208231B (en) | A kind of preparation method who treats diabetes Tibetan medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20131225 |